Dr. Louis Lacombe is a urologist-oncologist and clinical researcher at the CHU de Québec, and more specifically at L’Hôtel-Dieu de Québec.
Dr. Lacombe completed his medical training in Sherbrooke in 1988 and then completed a specialization in Urology at Laval University in 1993. Subsequently, Dr. Lacombe traveled to New York at the Memorial Sloan-Kettering Cancer Center associated with Cornell University to perform a subspecialisation in uro-oncology. This subspecialisation ended in 1996.
Following this subspecialisation, Dr. Lacombe joined the Urology Department of the CHU de Québec in July 1996. As a urologist, Dr. Lacombe specializes in complex surgeries associated with prostate, kidney, testicular and bladder cancer. He also collaborates in kidney transplant surgery.
Research at the Experimental Uro-oncology Laboratory aims to improve the diagnosis, prognosis, and therapy of prostate, bladder, and kidney cancers, and thus cover many aspects of research, from basic research to applied research. His interest is mainly focused on bladder cancer.
Dr. Lacombe is also actively involved in clinical research by conducting numerous Phase I, Phase II or Phase III clinical trials to test new drugs or therapies. He has been the principal investigator or co-investigator in more than 120 studies since the beginning of his career.
He has published more than 110 scientific papers and more than 250 scientific abstracts, and has presented at many international conferences.
Throughout his career, he has been awarded the FRQS Junior I and II Clinician Fellowship. He is currently a full professor in the Department of Surgery, and since 2016 he is the Director of the University Department of Surgery at the School of Medicine at Laval University.
10, rue McMahon
Canada G1R 2J6
Discordance between testosterone measurement methods in castrated prostate cancer patients.Journal Article
Endocr Connect, 8 (2), pp. 132-140, 2019, ISSN: 2049-3614.
Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.Journal Article
Eur Urol Focus, 5 (6), pp. 998-1006, 2019.
Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.Journal Article
BJU Int, 123 (4), pp. 624-631, 2019, ISSN: 1464-4096.
A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer.Journal Article
Cancer Epidemiol Biomarkers Prev, 28 (4), pp. 701-706, 2019, ISSN: 1055-9965.
Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada.Journal Article
Psychooncology, 28 (4), pp. 839-846, 2019, ISSN: 1057-9249.
Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody.Journal Article
Drug Metab Dispos, 47 (5), pp. 444-452, 2019, ISSN: 0090-9556.
Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series.Journal Article
Urol Oncol, 37 (5), pp. 300.e9-300.e15, 2019, ISSN: 1078-1439.
Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.Journal Article
PLoS Med, 16 (7), pp. e1002847, 2019, ISSN: 1549-1277.
Charlson Comorbidity Index as a Predictor of Cancer Mortality Beyond 10 Years after Radical ProstatectomyJournal Article
Clin Oncol (Belmont), 4 , pp. 1638 (5 pages), 2019.
Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?Journal Article
Clin Genitourin Cancer, 17 (6), pp. e1122-e1128, 2019, ISSN: 1558-7673.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
- Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., Subvention, Société de recherche sur le cancer, Compétition GRePEC (SRC/FRSQ/MDEIE), from 2012-10-01 to 2020-08-31
- The Contribution of Non-Classical 11-oxy Androgens to Prostate Cancer Progression, Subvention, Cancer de la prostate Canada, Subvention de découverte, from 2019-04-01 to 2022-03-30
Recently finished projects
- A Pan-Canadian initiative for the development of biomarker-driven approach to management of prostate cancer, Subvention, Centre hospitalier universitaire de Montréal, from 2012-04-01 to 2019-12-31
- Soutien à la recherche, Subvention, Université Laval - Soutien à la recherche, from 2017-07-01 to 2020-06-30